28 completed, 2 active not recruiting, 2 enrolling by invitation, 2 not yet recruiting. 12 Not applicable, 7 Phase 2, 6 Phase 3, 3 Phase 1, 1 Phase 4.
Follow HIV Prevention Trials Network: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| Characterization of Doxycycline Pharmacokinetics and Adherence Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group - Sexually Transmitted Infection | Phase 1 | Enrolling by invitation | HIV Prevention Trials Network | 16 | 2026-08-27 | 2026-09-17 |
| Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR DPP, 2PR, Free Choice - Pregnancy, HIV Infections | Phase 2 | Not yet recruiting | HIV Prevention Trials Network | 300 | 2026-05-15 | 2026-02-19 |
| Getting to Zero Among HHI MSM in the American South Health Access Coalitions, Social Media, Peer Support - HIV Infections | Not applicable | Enrolling by invitation | HIV Prevention Trials Network | 2700 | 2025-12-10 | 2026-03-13 |
| Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi PrEP eligibility assessment, Rapid HIV antibody testing prior to provision and/or refill of PrEP, PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines - HIV Infection, Sexually Transmitted Infections | Not applicable | Completed | HIV Prevention Trials Network | 199 | 2024-04-02 | 2025-12-12 |
| Testing a Barbershop-based HIV Prevention Initiative Among Men General, status-neutral HIV education, HIV self-test kits, Information about where to receive HIV prevention services - HIV Infections | Not applicable | Completed | HIV Prevention Trials Network | 271 | 2024-03-13 | 2026-10-20 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Active not recruiting | Gilead Sciences | 181 | 2023-12-13 | 2026-08-13 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Active not recruiting | Gilead Sciences | 253 | 2023-11-17 | 2026-08-17 |
| Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study Analytical Treatment Interruption - HIV Infection | Not applicable | Completed | HIV Vaccine Trials Network | 18 | 2022-08-22 | 2025-04-20 |
| INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care - HIV Infections, Drug Use | Not applicable | Completed | HIV Prevention Trials Network | 447 | 2021-06-02 | 2026-06-10 |
| Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study Analytical Treatment Interruption - HIV Infection | Not applicable | Completed | HIV Vaccine Trials Network | 13 | 2021-05-28 | 2026-03-13 |
| Pre-Exposure Prophylaxis for Transgender Women in the US and South America Immediate Intervention Arm, Deferred Intervention Arm - HIV Prevention | Phase 2 / Phase 3 | Completed | HIV Prevention Trials Network | 304 | 2021-03-26 | 2025-12-17 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants PGT121.414.LS, VRC07-523LS - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 33 | 2020-11-10 | 2024-12-13 |
| Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 Sample collection - SARS-CoV-2, COVID-19 | Completed | HIV Vaccine Trials Network | 760 | 2020-05-13 | 2026-01-12 | |
| A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia Community Adherence Clubs, Home-Based ART Delivery, Standard of Care - HIV Infections | Not applicable | Completed | HIV Prevention Trials Network | 2526 | 2017-05-01 | 2025-03-25 |
| Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study Truvada, Drug level counseling at Weeks 8 and 13 - HIV | Phase 4 | Completed | HIV Prevention Trials Network | 451 | 2016-10-12 | 2025-06-12 |
| Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States Intervention - HIV | Not applicable | Completed | HIV Prevention Trials Network | 144 | 2016-06-06 | 2025-03-25 |
| Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa Observational - HIV | Completed | HIV Prevention Trials Network | 401 | 2015-06-12 | 2025-03-27 | |
| Integrated Treatment and Prevention for People Who Inject Drugs Integrated Intervention - HIV Positive | Not applicable | Completed | HIV Prevention Trials Network | 1281 | 2015-02-04 | 2025-04-01 |
| Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART) Universal Testing with immediate ART, Universal Testing with ART eligibility according to National Guidelines, Standard of Care - HIV | Not applicable | Completed | HIV Prevention Trials Network | 48540 | 2014-01-01 | 2022-08-26 |
Showing 20 of 34. Sign in to see all of them.
HIV Infections (19) · Sexually Transmitted Diseases (3) · Acquired Immunodeficiency Syndrome (2) · COVID-19 (1) · HIV Seropositivity (1) · Hepatitis B (1) · Heterosexuality (1) · Opioid-Related Disorders (1) · Patient Compliance (1)
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (6) · Tenofovir (5) · Emtricitabine (3) · Standard of Care (2) · Watchful Waiting (2) · lenacapavir (2) · Atazanavir Sulfate (1) · BufferGel (1) · COVID-19 Testing (1) · Case Management (1) · Counseling (1) · Didanosine (1) · Dosage Forms (1) · HIV Testing (1) · Lamivudine (1)
United States (19) · South Africa (10) · Malawi (7) · Zimbabwe (7) · Brazil (5) · Zambia (5) · Thailand (4) · Peru (3) · Botswana (2) · India (2) · Kenya (2) · Uganda (2) · Argentina (1) · Eswatini (1) · Indonesia (1)
Shelly Karuna (3) · Katharine Bar (2) · Kenneth Mayer, MD (2) · Adriana Andrade, MD, MPH (1) · Alfred Chingono, MSc (1) · Amy Corneli, PhD (1) · Audrey Pettifor (1) · Audrey Pettifor, PhD (1) · Bernard Branson, MD (1) · Beryl Koblin, PhD (1) · Brenda Gati Mirembe, MBChB, MscEpi (1) · Catherine McPhail (1) · Chris Beyrer, MD (1) · Chris Beyrer, MD/MPH (1)
PMID 35393864, PMID 17453597, PMID 20368766, PMID 21330907, PMID 21546309, PMID 21767103, PMID 21943026, PMID 23129758, PMID 23183150, PMID 23277896, PMID 23334506, PMID 23874597, PMID 24056163, PMID 24602844, PMID 24698079, PMID 24742266, PMID 24898857, PMID 25103167, PMID 25962118, PMID 26862232, PMID 27405816, PMID 27421057, PMID 27424812, PMID 27530401, PMID 27708115, PMID 27811319, PMID 27815148, PMID 28182706, PMID 28464041, PMID 28471766, PMID 28628702, PMID 28665880, PMID 28697762, PMID 28828489, PMID 28872272, PMID 28964756, PMID 28966842, PMID 28986029, PMID 29016524, PMID 29238230, PMID 29251433, PMID 29369164, PMID 29420695, PMID 29608231, PMID 29659909, PMID 29672542, PMID 30027643, PMID 30027687, PMID 30096139, PMID 30157702
UM1AI068619 (10), U01AI068619 (3), UM1AI068614 (2), UM1AI068619-17 (2), 5UM1AI068614-14 (1), U01AI046749 (1), U01MH066687 (1), U01MH066688 (1), U01MH066701 (1), U01MH066702 (1)